Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Resolution of acute intestinal graft-versus-host disease (2019) Thiagarajan S, Neurath M, Hildner K Journal article, Review article Early Symptom Improvement With Risankizumab Treatment in Patients With Moderately to Severely Active Crohn's Disease: Analysis From a Phase 2 Study (2019) Feagan BG, Sandborn WJ, D'Haens GR, Panes J, Kaser A, Ferrante M, Louis E, et al. Conference contribution Predictors of Delayed Response to Tofacitinib: Results of the OCTAVE Open Study for Delayed Responders (2019) Regueiro M, Kinnucan JA, Ungaro R, Quirk D, Su C, Lawendy N, Fan H, et al. Conference contribution High level of EPA is associated with lower perivascular coronary attenuation as measured by coronary CTA (2019) Bittner DO, Göller M, Zopf Y, Achenbach S, Marwan M Conference contribution Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis (2019) Kremer A, Le Cleac'H A, Lemoinne S, Wolf K, De Chaisemartin L, Chollet-Martin S, Humbert L, et al. Journal article, Letter LUTATHERA (R) in first line therapy of G2 and G3 GEP-NETs (the NETTER-2 study) (2019) Ferone D, Pavel ME, Kunz P, De Herder W, Santoro P, Wegener A, Broberg P, et al. Conference contribution Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen (2019) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution Relation between objective tumour shrinkage and progression-free survival (PFS) in the NETTER-1 population (2019) Pavel ME, Broberg P, Caplin M, Ruszniewski P, Strosberg J, Santoro P, Ravasi L, Krenning E Conference contribution Ethanol consumption inhibits the development of autoimmunity by blocking IL-21 secretion in T-FH cells (2019) Azizov V, Dietel K, Kolenbrander A, Seubert S, Steffen F, Meidenbauer J, Steffen U, et al. Conference contribution THE NOX1/4 INHIBITOR GKT831 ACHIEVES CLINICALLY MEANINGFUL REDUCTIONS IN LIVER STIFFNESS, ATTENUATES CHOLESTASIS, AND IMPROVES QUALITY OF LIFE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (2019) Huang JC, Invernizzi P, Dalekos GN, Nevens F, Van Vlierberghe H, Zigmond E, Andrade RJ, et al. Conference contribution